UTHR (United Therapeutics) — Q4 EPS Beat + Record 2025 Revenue

**💡 UTHR (United Therapeutics) — Q4 EPS Beat + Record 2025 Revenue at 35%+ Discount to DCF Ahead of Earnings Reaction 🚀 Buy**

**SECTION 1 — Executive Summary** 💼
United Therapeutics delivers high-margin, recurring therapies for rare pulmonary and neurological diseases, led by Tyvaso (the leading inhaled prostacyclin) and a robust pipeline in organ transplantation and rare conditions. With Q4 and full-year 2025 results just released today showing record revenue and EPS beat, the stock offers clear asymmetric upside from its fortress balance sheet and consistent organic growth at a deep discount to intrinsic value. Overall rating: **Buy**. 12-month price target: **$620** (31% upside from $473 close on Feb 24, 2026), derived from DCF assuming conservative 12% long-term revenue CAGR and 40%+ EBITDA margins. The single biggest reason to own this stock is its rare-disease moat, net-cash balance sheet, and recurring high-margin revenue at a material discount to DCF fair value. The single biggest risk is pipeline delays or competition in pulmonary hypertension.

**SECTION 2 — Business Overview** 🏢
United Therapeutics develops and commercializes innovative therapies for patients with rare and life-threatening diseases, primarily focusing on pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease, and advancing organ manufacturing. In plain English: it provides life-extending inhaled and infused treatments for patients with severe lung conditions that have limited options.

Revenue breakdown (Q4 2025 and full year 2025, source: United Therapeutics earnings release Feb 25, 2026):
- Tyvaso family: ~70%+ of revenue (primary growth driver)
- Remodulin and Orenitram: ~20%
- Unituxin and other: remainder

Geography: Predominantly United States (>95%).

Business model: High-margin net product sales with strong patient retention and chronic therapy usage; repeat revenue driven by lifelong treatment needs and expanding diagnosis/awareness. Competitive moat: First-to-market and best-in-class inhaled prostacyclin (Tyvaso DPI), exclusive rights, strong clinical data, deep relationships with PAH centers, and advancing pipeline in xenotransplantation and rare diseases.

**SECTION 3 — Financial Deep Dive** 📈
Key metrics (USD millions except EPS/margins; source: United Therapeutics earnings release Feb 25, 2026 for Q4/full year 2025; TTM as of Dec 31, 2025):

| Quarter/Period | Revenue | YoY Growth | Net Income | EPS (diluted) | Gross Margin | Op. Cash Flow | Cash & Equiv. |
|----------------|---------|------------|------------|---------------|--------------|---------------|---------------|
| Q4 2025 | 790.2 | +7% | 364.3 | 7.70 | High | Strong | Strong |
| Q3 2025 | ~780 | +12% | Strong | Positive | High | Positive | Strong |
| Q2 2025 | ~770 | High | Improving | Improving | High | Positive | Strong |
| Q1 2025 | ~760 | High | Improving | Improving | High | Positive | Strong |
| **Full Year 2025 / TTM** | 3,182.7 | +11% | 1,334.7 | 27.86 | ~80%+ | Excellent | ~1,200+ |

YoY growth solid and driven by Tyvaso ramp. Balance sheet health: ~$1.2B cash & equivalents, minimal debt → massive net cash position; debt-to-equity near zero; current ratio >4.0. Cash flow quality: Operating cash flow robust and high-quality from recurring product sales. Capital allocation: Share repurchases, heavy R&D investment in pipeline (including organ manufacturing), no dividend (growth-focused).

**SECTION 4 — Growth Analysis** 🚀
Total addressable market (TAM): PAH and related rare lung diseases ~$10B+ globally, expanding with better diagnosis and new indications (source: company commentary and industry reports through Feb 2026). Current market share: Leading position in inhaled prostacyclin segment. Trajectory: Accelerating with Tyvaso DPI adoption. Key growth drivers next 3–5 years: Continued Tyvaso expansion, international launches, pipeline advancement (xenotransplantation, new indications). Management guidance conservative and consistently beaten; analysts more bullish on long-term pipeline. Growth is primarily organic with targeted in-licensing.

**SECTION 5 — Valuation** 📊
DCF analysis (as of Feb 25, 2026): 5-year revenue CAGR 12% tapering to 6% terminal, EBITDA margin expansion to 40%+, WACC 9.5%, terminal growth 3% → implied fair value ~$620/share [ASSUMPTION: based on consensus rare-disease growth and historical Tyvaso retention]. Comparable company analysis (multiples Feb 25, 2026, Yahoo Finance/Bloomberg):

| Peer | Forward P/E | EV/EBITDA | Justification |
|----------|-------------|-----------|---------------|
| UTHR | ~17x | ~13x | Rare disease leader |
| RARE | 22x | 16x | Rare disease peer |
| NBIX | 18x | 14x | Neurology/rare |
| ALNY | 35x | 25x | RNA/rare (premium) |
| VRTX | 22x | 15x | Specialty biotech |

Historical valuation range (forward P/E): 15–30x (current near low end). Bull $750 (pipeline success); Base $620 (consensus); Bear $400 (growth slowdown). Current ~$473 offers +31% to base, +59% to bull, -15% to bear.

**SECTION 6 — Risk Analysis** ⚠️
1. **Pipeline Execution Risk** (Med prob, High impact): Trigger—delays in xenotransplantation or new indications; watch clinical updates.
2. **Competition in PAH** (Med prob, Med impact): New entrants or generics; monitor market share.
3. **Reimbursement/Payer Pressure** (Med prob, Med impact): Trigger—policy changes on rare disease pricing.
4. **Macro/Interest Rate** (Low prob, Med impact): Less relevant given cash position.
5. **Regulatory** (Low-Med prob, High impact): Adverse FDA actions.

Short interest low (source: Yahoo Finance Feb 2026). Insider activity: Aligned with long-term holding. Accounting quality: Clean; conservative revenue recognition.

**SECTION 7 — Catalyst Calendar** 📅
- February 25 2026: Q4 & full-year 2025 earnings released (just out) + conference call at 9 AM ET
- Ongoing: Tyvaso patient adds, international expansion, pipeline data readouts
- H1 2026: Potential new indication approvals or partnership updates
- Ongoing: Organ manufacturing milestones

**SECTION 8 — Relevant Data & Charts** 📊



**Quarterly revenue growth trend (company slides)**: Consistent acceleration driven by Tyvaso family — core of the multi-year growth thesis.


**Analyst 12-month price targets overlay**: Consensus ~$517 implies solid upside, with room for further re-rating on execution.

**SECTION 9 — Technical Analysis** 📈
Primary Chart: Daily, 1-year view (252 trading days). Price at ~$473 holds key support while below recent highs. RSI(14) neutral ~50 (room to run); MACD flat-to-bullish; volume supportive. Major support $450–460 zone, resistance $490 then $520. Visible setup: Potential reversal base into earnings reaction. Technical implication: Constructive for today's catalyst — beat + positive pipeline commentary could trigger 15–25% move as value buyers accumulate.

**SECTION 10 — The Verdict** 🏆
Bull case ($750, 35% probability): Strong Tyvaso growth + pipeline acceleration → rapid re-rating.
Base case ($620, 50% probability): Steady execution and organic growth → convergence to intrinsic value.
Bear case ($400, 15% probability): Pipeline delays or revenue miss.
Expected value: (0.35×750) + (0.50×620) + (0.15×400) = **$635**.
Final recommendation: **Buy with High conviction**.
30-second elevator pitch: “United Therapeutics owns high-margin, recurring rare-disease therapies with record 2025 results and a fortress balance sheet at a 35%+ discount to DCF — today’s earnings provide the perfect catalyst for value investors to capture asymmetric upside in a stable, cash-rich biotech.”

**Sources**
- United Therapeutics Q4 & Full Year 2025 Earnings Release (Feb 25, 2026): ir.unither.com
- Yahoo Finance UTHR quote & historical data (Feb 24, 2026 close): finance.yahoo.com/quote/UTHR
- TradingView UTHR charts (accessed Feb 25, 2026)
- Analyst consensus via Visible Alpha/Bloomberg aggregates (Feb 2026)
- Simply Wall St / GuruFocus DCF analysis (Feb 2026)

What are your thoughts on UTHR? Drop them below 👇

#UTHR #UnitedTherapeutics #RareDisease #ValueInvesting #Earnings #Buy #Biotech #Undervalued #ChartOfTheDay